No headlines found.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, ABIO, MODN
Globe Newswire (Mon, 15-Apr 8:38 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANSS, HRT, CHX, ABIO
PRNewswire (Wed, 10-Apr 2:04 PM ET)
PRNewswire (Tue, 9-Apr 8:10 PM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, MODN, ABIO
Globe Newswire (Mon, 8-Apr 2:25 PM ET)
Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm
PRNewswire (Sat, 6-Apr 1:05 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIK, CHX, KTRA, ABIO
PRNewswire (Sat, 6-Apr 12:59 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, KTRA, ABIO
Globe Newswire (Fri, 5-Apr 1:44 PM ET)
Business Wire (Fri, 5-Apr 1:27 PM ET)
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
Globe Newswire (Wed, 3-Apr 7:30 AM ET)
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Arca Biopharma trades on the NASDAQ stock market under the symbol ABIO.
As of April 19, 2024, ABIO stock price climbed to $3.32 with 809,937 million shares trading.
ABIO has a beta of -0.28, meaning it tends to be less sensitive to market movements. ABIO has a correlation of 0.00 to the broad based SPY ETF.
ABIO has a market cap of $48.14 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ABIO stock traded as high as $3.90 and as low as $1.56.
The top ETF exchange traded funds that ABIO belongs to (by Net Assets): VTI, VXF, DFAT, DFSU.
ABIO has outperformed the market in the last year with a price return of +66.0% while the SPY ETF gained +21.1%. ABIO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +106.2% and +7.8%, respectively, while the SPY returned +4.2% and -3.5%, respectively.
ABIO support price is $3.14 and resistance is $3.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABIO stock will trade within this expected range on the day.